Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SPX-602
- Development stage
- Preclinical
- Lead developer
- SparX Biopharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SPX-602 is a bispecific antibody-drug conjugate (ADC) developed by SparX Biopharmaceutical, utilizing their proprietary Nab2 dual-payload platform. It is designed to simultaneously target Vascular Endothelial Growth Factor (VEGF) and Programmed Death-Ligand 1 (PD-L1), combining anti-angiogenic and immune checkpoint inhibition strategies. The conjugate delivers two distinct cytotoxic payloads: a Topoisomerase 1 (TOP1) inhibitor and Monomethyl Auristatin E (MMAE), which work synergistically to induce tumor cell death via DNA damage and microtubule disruption. This dual-payload approach is intended to enhance efficacy and overcome resistance in heterogeneous tumors. SPX-602 is currently in IND-enabling studies for the treatment of various cancers.
- Other names
- VEGF-PD-L1-ADC (dual-payload: TOP1 inhibitor × MMAE)
02
Targets
TOP1 (DNA Topoisomerase I)PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on SPX-602.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SPX-602.